
Elisabetta Fenocchio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/803546/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index. Journal of Gastrointestinal Cancer, 2022, 53, 289-298.	1.3	6
2	Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis. Journal of Chemotherapy, 2022, 34, 123-132.	1.5	1
3	Delta-Radiomics Predicts Response to First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients with Liver Metastases. Cancers, 2022, 14, 241.	3.7	14
4	Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. , 2022, 10, e004001.		45
5	Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer. European Journal of Cancer, 2022, 172, 171-181.	2.8	14
6	Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial Journal of Clinical Oncology, 2021, 39, 3506-3506.	1.6	53
7	A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index. Journal of Gastrointestinal Cancer, 2021, , 1.	1.3	0
8	The Pan-Immune-Inflammation Value in microsatellite instability–high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. European Journal of Cancer, 2021, 150, 155-167.	2.8	45
9	Pursuit of Gene Fusions in Daily Practice: Evidence from Real-World Data in Wild-Type and Microsatellite Instable Patients. Cancers, 2021, 13, 3376.	3.7	8
10	Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. , 2021, 9, e003370.		10
11	The prognostic nutritional index predicts survival and response to firstâ€line chemotherapy in advanced biliary cancer. Liver International, 2020, 40, 704-711.	3.9	42
12	Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures. Cancers, 2020, 12, 3256.	3.7	8
13	Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer?. Cancers, 2019, 11, 1547.	3.7	10
14	Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives. Expert Opinion on Pharmacotherapy, 2019, 20, 2121-2137.	1.8	7
15	Improvement of Metastatic Colorectal Cancer Patient Survival: Single Institution Experience. Cancers, 2019, 11, 369.	3.7	4
16	HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. Oncologist, 2019, 24, 1395-1402.	3.7	95
17	Emerging molecular target antagonists for the treatment of biliary tract cancer. Expert Opinion on Emerging Drugs, 2018, 23, 63-75.	2.4	14
18	Rationale for the use of metronomic chemotherapy in gastrointestinal cancer. Expert Opinion on Pharmacotherapy, 2018, 19, 1451-1463.	1.8	5

#	Article	IF	CITATIONS
19	Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR. PLoS ONE, 2018, 13, e0191593.	2.5	12
20	Improvement of metastatic colorectal cancer patient survival: Single institution experience Journal of Clinical Oncology, 2018, 36, e15633-e15633.	1.6	0
21	Successful treatment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: a case report. BMC Cancer, 2016, 16, 793.	2.6	8